---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-063531"
form_type: "8-K"
ticker: "CTXR"
cik: "0001506251"
company_name: "Citius Pharmaceuticals, Inc."
filed_at: "2026-06-01T20:30:19+00:00"
generated_at: "2026-06-01T20:39:39.511162+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Citius Oncology reports Phase 1 combo data: 24% ORR, 33% in endometrial cancer; Phase 2 planned

## Summary
- Phase 1 trial of LYMPHIR + pembrolizumab in 25 heavily pre-treated gynecologic cancer patients showed 24% ORR (5 partial responses); median duration of response not reached.
- In endometrial cancer patients previously treated with checkpoint inhibitors, ORR was 33%; one response ongoing >3 years.
- 48% of 21 evaluable patients achieved clinical benefit; median PFS among that group was 20.5 months.
- Safety manageable: only one Gr 3 CLS at highest dose; no new safety signals or Gr 3+ immune-related AEs.
- A Phase 2 expansion study is being planned to further evaluate the combo in gynecologic cancers.

## SEC filing metadata
- accession: 0001213900-26-063531
- form_type: 8-K
- ticker: CTXR
- cik: 0001506251
- company_name: Citius Pharmaceuticals, Inc.
- filed_at: 2026-06-01T20:30:19+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1506251/000121390026063531/0001213900-26-063531-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1506251/000121390026063531/ea0292904-8k_citius.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-063531
- JSON: https://secwatch.observer/filing/0001213900-26-063531.json
- Plain text: https://secwatch.observer/filing/0001213900-26-063531.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.